New study to track Real-World safety of zavicefta in sickest patients
NCT ID NCT06864585
First seen Nov 01, 2025 · Last updated May 04, 2026 · Updated 22 times
Summary
This study will observe 59 patients in Japan who receive Zavicefta for the first time to treat serious infections. It focuses on those with sepsis (a severe blood infection) or reduced kidney function. Researchers will track side effects and how well the drug works over 28 days. The goal is to gather real-world safety data, not to test a new treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFECTIOUS DISEASES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.